Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Tarsus Pharmaceuticals, Inc. - Common Stock
(NQ:
TARS
)
64.82
-2.29 (-3.41%)
Streaming Delayed Price
Updated: 12:49 PM EDT, Jun 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tarsus Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
August 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
July 31, 2023
Via
Benzinga
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
July 31, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
↗
July 26, 2023
Via
Benzinga
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
↗
December 15, 2022
Via
Benzinga
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
↗
July 25, 2023
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 25, 2023
Via
Benzinga
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
July 25, 2023
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54.
Via
Benzinga
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
July 25, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
↗
July 20, 2023
The company's lead therapy is getting close to the finish line of FDA approval.
Via
The Motley Fool
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
July 20, 2023
Gainers PainReform Ltd. (NASDAQ: PRFX) jumped 45.5% to $10.34 after declining 8% on Wednesday. PaiReform recently regained compliance with Nasdaq continued listing requirements.
Via
Benzinga
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Climbs to New 52-Week High
July 20, 2023
Via
Investor Brand Network
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday
↗
July 20, 2023
U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares rose...
Via
Benzinga
Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis
June 12, 2023
Webcast scheduled for Thursday, June 15 at 8:30am PT
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present at the Jefferies Global Healthcare Conference
June 05, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
↗
July 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
↗
May 18, 2023
Via
Benzinga
Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements
May 09, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers
May 08, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Participate at the Bank of America 2023 Healthcare Conference
May 03, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
April 24, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
↗
April 18, 2023
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA).
Via
Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
↗
March 28, 2023
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,...
Via
Benzinga
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
March 13, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present at Upcoming Investor Conferences
March 02, 2023
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough
↗
February 23, 2023
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...
Via
Benzinga
Tarsus Added to NASDAQ Biotechnology Index
December 16, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
December 15, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
November 09, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
October 25, 2022
From
Tarsus Pharmaceuticals, Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
